The launch of Zyrtec OTC and its private label equivalent, Private Label Cetirizine, in early 2008 triggered strong incremental growth in the over-the-counter (OTC) allergy medication market in the U.S., a new analysis by NielsenHealth and Wolters Kluwer Health reports.
According to Nielsen and Wolters Kluwer, the OTC oral/nasal allergy market grew by about 30% in the first half of 2008, compared with same period in 2007.
Like Zyrtec OTC, PL Cetirizine had rapid uptake, accounting for approximately one-third of the OTC cetirizine market’s patient volume during the spring 2008 allergy season.  Zyrtec …